8. Immunomodulators and antineoplastics

8.2. Antineoplastics and supportive medicines

8.2.1. Cytotoxic medicines

Vinblastine

- **Indication**: Kaposi sarcoma of unspecified primary site
- **ICD11 code**: 2C27.Z

- **INN**: Vinblastine
- **Medicine type**: Chemical agent
- **List type**: Complementary

- **Additional notes**: For intravenous use only

- **Formulations**: Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)

- **EML status history**: First added in 2015 (TRS 994)
  Changed in 2021 (TRS 1035)

- **Sex**: All
- **Age**: Adolescents and adults

- **Therapeutic alternatives**: The recommendation is for this specific medicine

- **Patent information**: Patents have expired in most jurisdictions
  Read more about patents.

- **Tags**: Cancer

- **Wikipedia**: Vinblastine
- **DrugBank**: Vinblastine

---

**Summary of evidence and Expert Committee recommendations**

The Expert Committee recommended the addition of new formulation of vinblastine IV injection (10 mg/10 mL) to the EML and EMLc.

**Expert Committee report**